Agenus (AGEN) Competitors $5.93 +0.42 (+7.62%) Closing price 03:57 PM EasternExtended Trading$6.01 +0.08 (+1.35%) As of 04:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock AGEN vs. MYGN, ZBIO, EBS, LXRX, RIGL, CBIO, XOMA, VNDA, VSTM, and CDXSShould you be buying Agenus stock or one of its competitors? The main competitors of Agenus include Myriad Genetics (MYGN), Zenas BioPharma (ZBIO), Emergent Biosolutions (EBS), Lexicon Pharmaceuticals (LXRX), Rigel Pharmaceuticals (RIGL), Crescent Biopharma (CBIO), XOMA Royalty (XOMA), Vanda Pharmaceuticals (VNDA), Verastem (VSTM), and Codexis (CDXS). These companies are all part of the "biotechnology" industry. Agenus vs. Its Competitors Myriad Genetics Zenas BioPharma Emergent Biosolutions Lexicon Pharmaceuticals Rigel Pharmaceuticals Crescent Biopharma XOMA Royalty Vanda Pharmaceuticals Verastem Codexis Agenus (NASDAQ:AGEN) and Myriad Genetics (NASDAQ:MYGN) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, dividends, valuation, institutional ownership, profitability and risk. Which has more risk & volatility, AGEN or MYGN? Agenus has a beta of 1.51, suggesting that its share price is 51% more volatile than the S&P 500. Comparatively, Myriad Genetics has a beta of 1.91, suggesting that its share price is 91% more volatile than the S&P 500. Which has preferable valuation & earnings, AGEN or MYGN? Myriad Genetics has higher revenue and earnings than Agenus. Myriad Genetics is trading at a lower price-to-earnings ratio than Agenus, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAgenus$103.46M1.57-$227.21M-$8.67-0.68Myriad Genetics$837.60M0.62-$127.30M-$1.12-5.00 Is AGEN or MYGN more profitable? Myriad Genetics has a net margin of -12.20% compared to Agenus' net margin of -196.12%. Agenus' return on equity of 0.00% beat Myriad Genetics' return on equity.Company Net Margins Return on Equity Return on Assets Agenus-196.12% N/A -82.33% Myriad Genetics -12.20%-4.95%-3.39% Do institutionals & insiders hold more shares of AGEN or MYGN? 61.5% of Agenus shares are held by institutional investors. Comparatively, 99.0% of Myriad Genetics shares are held by institutional investors. 5.5% of Agenus shares are held by insiders. Comparatively, 2.4% of Myriad Genetics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Do analysts prefer AGEN or MYGN? Agenus currently has a consensus price target of $14.00, suggesting a potential upside of 136.09%. Myriad Genetics has a consensus price target of $14.38, suggesting a potential upside of 156.87%. Given Myriad Genetics' higher probable upside, analysts plainly believe Myriad Genetics is more favorable than Agenus.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Agenus 0 Sell rating(s) 4 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33Myriad Genetics 2 Sell rating(s) 10 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.13 Does the media favor AGEN or MYGN? In the previous week, Myriad Genetics had 1 more articles in the media than Agenus. MarketBeat recorded 2 mentions for Myriad Genetics and 1 mentions for Agenus. Agenus' average media sentiment score of 0.00 equaled Myriad Genetics'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Agenus 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Myriad Genetics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryMyriad Genetics beats Agenus on 10 of the 15 factors compared between the two stocks. Get Agenus News Delivered to You Automatically Sign up to receive the latest news and ratings for AGEN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AGEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AGEN vs. The Competition Export to ExcelMetricAgenusMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$151.07M$2.91B$5.54B$8.95BDividend YieldN/A2.42%5.38%4.08%P/E Ratio-0.6821.5627.4020.04Price / Sales1.57281.10419.46118.60Price / CashN/A41.9536.6357.47Price / Book-0.457.518.085.67Net Income-$227.21M-$55.05M$3.16B$248.47M7 Day Performance20.77%3.16%2.12%2.90%1 Month Performance18.60%5.92%4.43%5.75%1 Year Performance-59.19%5.82%35.62%21.36% Agenus Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AGENAgenus4.0702 of 5 stars$5.93+7.6%$14.00+136.1%-61.4%$151.07M$103.46M-0.68440MYGNMyriad Genetics4.2632 of 5 stars$5.31+1.1%$14.38+170.9%-77.3%$489.48M$837.60M-4.742,700ZBIOZenas BioPharma1.6622 of 5 stars$9.69+1.1%$36.67+278.4%N/A$405.37M$15M-2.73N/AGap UpEBSEmergent Biosolutions3.9989 of 5 stars$6.38+0.5%$14.33+124.7%-5.5%$346.31M$1.04B-2.352,420LXRXLexicon Pharmaceuticals2.5184 of 5 stars$0.95+15.2%$3.67+287.7%-42.8%$341.86M$31.08M-1.85140News CoverageRIGLRigel Pharmaceuticals2.8517 of 5 stars$18.73-3.9%$36.40+94.3%+121.5%$334.71M$179.28M9.05160CBIOCrescent Biopharma3.2961 of 5 stars$16.14+1.5%$25.00+54.9%N/A$315.54M$10K-0.3526News CoverageHigh Trading VolumeXOMAXOMA Royalty4.4356 of 5 stars$25.20-8.3%$69.50+175.8%+6.0%$301.64M$28.49M-21.9110High Trading VolumeVNDAVanda Pharmaceuticals4.4178 of 5 stars$4.72-1.3%$16.50+249.6%-7.2%$278.15M$198.77M-6.29290VSTMVerastem2.8666 of 5 stars$4.15flat$13.38+222.3%+65.2%$228.04M$10K-1.3050CDXSCodexis3.092 of 5 stars$2.44+2.1%$11.00+350.8%-2.8%$202.15M$59.35M-2.46250Positive News Related Companies and Tools Related Companies Myriad Genetics Alternatives Zenas BioPharma Alternatives Emergent Biosolutions Alternatives Lexicon Pharmaceuticals Alternatives Rigel Pharmaceuticals Alternatives Crescent Biopharma Alternatives XOMA Royalty Alternatives Vanda Pharmaceuticals Alternatives Verastem Alternatives Codexis Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AGEN) was last updated on 7/3/2025 by MarketBeat.com Staff From Our PartnersTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe $100 Trillion AI Story No One Is Telling YouJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Agenus Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Agenus With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
